Moderna mRNA cancer vaccine clears Phase 3, CanSino jumps 50%

Moderna's first positive Phase 3 mRNA cancer vaccine result triggered a sector-wide repricing, lifting CanSino Biologics shares more than 50 percent.

Moderna's first positive Phase 3 result for a personalized mRNA cancer vaccine confirms the individualized neoantigen approach, sending shares up 177 percent and lifting CanSino Biologics more than 50 percent.

"This is the first phase 3 study to show that intismeran, a treatment designed based on the unique mutational 'fingerprint' of a patient's own tumor, given in combination with pembrolizumab can reduce the risk of recurrence or death," Georgina Long, principal investigator and medical director of Melanoma Institute Australia, said.

The INTerpath-001 trial enrolled 1,137 patients with completely resected stage IIB-IV melanoma, randomized 2:1 to receive intismeran plus Keytruda or Keytruda alone. The combination achieved statistically significant improvements in recurrence-free survival and distant metastasis-free survival at a pre-specified interim analysis, with no new safety signals. Full hazard ratios have not yet been disclosed.

Moderna added roughly $40 billion in market capitalization on the news, while CanSino Biologics (06185.HK) surged more than 50 percent in Hong Kong trading on Aug. 20. Analysts project multi-billion dollar peak sales for intismeran, and the result extends beyond melanoma — Moderna is studying the same platform in non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

CanSino's LNP Platform Draws Parallels

CLSA analysts said CanSino's development roadmap and antigen design are broadly similar to Moderna's, with one key difference: CanSino's three-component lipid nanoparticle delivery system, which the firm says is safer than traditional formulations and may support stronger cellular immune responses. CanSino's rhabdomyosarcoma program is at the investigator-initiated trial stage, while its glioma program awaits preclinical approval.

The Phase 3 result builds on five-year follow-up data from the Phase 2b KEYNOTE-942 trial, presented at the 2026 ASCO Annual Meeting, which showed the combination cut the risk of recurrence or death by 49 percent (hazard ratio 0.51) and the risk of distant metastasis or death by 59 percent (hazard ratio 0.411) versus pembrolizumab alone.

Intismeran works by sequencing a patient's own tumor to identify its unique mutational signature, then encoding up to 34 tumor-specific neoantigens into a synthetic mRNA designed to train the immune system to recognize and attack the cancer. The drug has received FDA Breakthrough Therapy Designation, which could support an expedited review pathway.

Repricing Spreads Across AI Healthcare

The market reaction extended beyond mRNA vaccine developers. Tempus AI rose more than 24 percent and Twist Bioscience gained more than 22 percent, as investors reassessed the data-intensive nature of personalized cancer vaccines. Each patient requires genomic sequencing, mutation analysis, neoantigen prediction, and personalized manufacturing — a workflow that increases demand for sequencing infrastructure, clinical data platforms, and computational biology tools.

William Blair analysts upgraded Moderna to Outperform from Market Perform, citing "clear line of sight to revenue diversification from the COVID business." RBC Capital Markets noted the readout came earlier than expected, with analysts writing that "the strength of the underlying data must have been compelling to trigger significance at the interim analysis."

Moderna's Q2 2026 results showed revenue of $145 million with a net loss of $782 million, and approximately $6.9 billion in cash and investments. The company's recent FDA approval of mFLUSIVA, the first mRNA flu shot authorized in the United States, adds to its respiratory vaccine franchise beyond COVID-19.

For CanSino, the question is whether its earlier-stage programs can replicate Moderna's clinical trajectory. The company's cash position and pipeline execution will determine whether it can convert the sector tailwind into tangible clinical milestones. Merck, Moderna's partner on intismeran, also rose as much as 11 percent, and the Nasdaq Biotechnology Index hit a record — a sign that investors are pricing in broader validation of the mRNA oncology platform beyond a single indication.

This article is for informational purposes only and does not constitute investment advice.